Back to search
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy trials you may qualify forThe MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease…
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of…
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with A…
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosi…
This is a single-center observational study evaluating the potential value of NfL as a biomarker for diagnosis, detection of disease onset, monitoring of diseas…
ATTRv amyloidosis is a systemic disease with two clinical forms, neurological and cardiological, which are sometimes combined (so-called mixed forms). Patisira…
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with hereditary transthyretin-mediated…